Recombinant Cynomolgus Siglec-15 / CD33L3 Protein, His Tag, 100 µg

Background
Siglec-15 is a DAP12-associated immunoreceptor, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Siglecs are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. Siglec-15 consisting of immunoglobulin (Ig)-like domains, transmembrane domain and a short cytoplasmic tail. Siglec-15 is that recognizes sialylated glycans and regulates osteoclast differentiation. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.

Source
Recombinant Cynomolgus Siglec-15, His Tag (SG5-C52H6) is expressed from human 293 cells (HEK293). It contains AA Phe 20 - Thr 263 (Accession # A0A2K5UY47-1).
Predicted N-terminus: Phe 20

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.1 kDa. The protein migrates as 30-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS with Arginine, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor"
Kobayashi, Terkawi, Ota et al
Bone Res (2024) 12 (1), 35
(2) "Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape"
Zhang, Shi, Jin et al
Cancer Commun (Lond) (2024)
(3)  "The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma"
Sun, Du, Xu et al
Clin Respir J (2024) 18 (5), e13772
Showing 1-3 of 109 papers.